Myeloid Cell Immune Checkpoint targeted Reporter Gene Assay Service

Myeloid Cell Immune Checkpoints Show Great Targeting Potential in Cancer Immunotherapy.

Myeloid cells, regulated by myeloid cell immune checkpoints, are the most abundant cell type present in solid tumors and play a pivotal role in tumor microenvironment (TME) by either eliminating tumor cells through phagocytosis or promoting anti-tumor immunity. However, they can also promote tumor growth by engaging with receptors expressed on other immune or cancer cells. The dual role of myeloid cells highlights the therapeutic potential of targeting myeloid checkpoints in cancer immunotherapy.

Fig.1 Myeloid cell function modulated by putative immune checkpoint molecules in human TME.^{1, 2}

Myeloid Cell Immune Checkpoints-targeted Reporter Gene Assay at Creative Biolabs

Cell-based reporter gene assays offer a more efficient and reproducible method compared to primary cell-based assays for evaluating the function of myeloid cell immune checkpoints-targeted therapies. Creative Biolabs has developed an advanced myeloid cell immune checkpoints-targeted reporter gene assay that harnesses these advantages, providing a powerful and reliable tool for assessing the efficacy of candidates.

Our cutting-edge cell-based reporter gene assays feature expertly engineered reporter cell lines that express myeloid cell immune checkpoints. These checkpoints, when engaged by their ligands, trigger signaling cascades that lead to the activation of distinct genetic markers. This activation yields quantifiable data, enabling precise evaluation of therapeutic compound efficacy. Importantly, our stringent quality assurance protocols ensure the precise and dependable results of all measurements. In addition, if customers would like to perform this assay own, we also provide reporter cell line construction services to produce desired products that are responsive specifically to the immune checkpoints of interest. Collectively, our team of seasoned professionals excels in crafting tailored solutions to meet individual customer requirements, guaranteeing high-quality outcomes with speedy turnaround times.

Fig.2 Workflow of our assay.

Our High-click Myeloid Cell Immune Checkpoints-targeted Reporter Gene Assay & Products

Recognizing the pivotal role of myeloid cell immune checkpoints in cancer therapy, Creative Biolabs has developed a suite of specialized reporter gene assays. By employing engineered myeloid cell lines with optimal reporter systems, these assays enable researchers to quantify the efficacy of potential therapeutics accurately and effectively. Here, we showcase some of our top myeloid cell checkpoint-targeted reporter gene assays.

• CD47-Sirpa-targeted Reporter Gene Assay

At the same time, we also offer mature kits to choose from for customers' projects:

EasyMeasure™ SIRPα/CD47 Blockade Bioassay Kit, Fc-Null

EasyMeasure™ SIRPα/CD47 Blockade Bioassay Kit, Fc-Dependent

Frequently Employed Reporter Genes

• Luciferase: Generates measurable bioluminescence.
• Green Fluorescent Protein (GFP): Fluoresces under specific light conditions, detectable via fluorescence microscopy or flow cytometry.
• β-galactosidase: Produces a color change in the presence of a specific substrate.

Sample Compatibility

Our assay is versatile and can be applied to a wide range of samples, encompassing antibodies and numerous biologics. For assistance with your particular samples, please contact our technical support team.

• Antibodies: monoclonal antibodies, BsAb antibodies, and other antibody formats.
• Small molecular: chemical compounds and short peptides

Attractive Features

• Quantitative
• High-throughput
• Easy-to-operate
• 2-week timeline.

Customer Review

Q & A

1. Q1: How can the data from these assays be interpreted?

   A1: Data interpretation involves comparing the reporter gene signal in treated versus untreated or control samples. Increased or decreased signal intensity indicates modulation of the immune checkpoint activity by the test compounds or conditions.

2. Q2: How about the requirements considering sample shipment?

   A2: For our myeloid cell immune checkpoints-targeted reporter gene assay, we require customers to provide essential details about their candidates, including molecular weight, targets, purity, concentration, endotoxin level, and any properties that could affect the assay results. Upon reviewing your request, our specialized team will evaluate your project and deliver tailored recommendations. Upon your agreement to our recommendations, we will commence the implementation plan after receiving your samples.

For more information on our myeloid cell immune checkpoint-targeted reporter gene assay, please feel free to contact us.

References

1. Chan, Chilam, et al. "Targeting myeloid checkpoint molecules in combination with antibody therapy: a novel anti-cancer strategy with IgA antibodies?." Frontiers in Immunology 13 (2022): 932155.
2. under Open Access License CC BY 4.0, without modification.

For Research Use Only.